Celgene (NASDAQ:CELG) was upgraded by research analysts at Barclays from an “equal weight” rating to an “overweight” rating in a research report issued to clients and investors on Tuesday, The Fly reports.

Several other brokerages have also recently commented on CELG. BMO Capital Markets lifted their price objective on shares of Celgene from $148.00 to $155.00 and gave the company an “outperform” rating in a research note on Friday, November 17th. Cantor Fitzgerald set a $112.00 price objective on shares of Celgene and gave the company a “hold” rating in a research note on Wednesday, January 17th. Oppenheimer restated a “buy” rating and set a $170.00 price objective on shares of Celgene in a research note on Friday, October 20th. Vetr upgraded shares of Celgene from a “buy” rating to a “strong-buy” rating and set a $144.39 price objective for the company in a research note on Monday, October 23rd. Finally, Cann restated a “buy” rating on shares of Celgene in a research note on Thursday, October 26th. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating, eighteen have assigned a buy rating and two have assigned a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $130.35.

Shares of Celgene (NASDAQ:CELG) opened at $91.51 on Tuesday. The company has a debt-to-equity ratio of 2.29, a quick ratio of 4.80 and a current ratio of 4.99. Celgene has a 12 month low of $88.32 and a 12 month high of $147.17. The company has a market cap of $69,583.77, a P/E ratio of 25.56, a price-to-earnings-growth ratio of 0.66 and a beta of 1.49.

Celgene (NASDAQ:CELG) last announced its quarterly earnings data on Thursday, January 25th. The biopharmaceutical company reported $1.87 EPS for the quarter, beating the consensus estimate of $1.78 by $0.09. Celgene had a net margin of 22.38% and a return on equity of 67.50%. The business had revenue of $3.48 billion during the quarter, compared to analysts’ expectations of $3.46 billion. During the same period in the previous year, the business posted $1.61 EPS. The business’s quarterly revenue was up 16.9% compared to the same quarter last year. equities research analysts predict that Celgene will post 7.68 earnings per share for the current year.

In related news, insider Mark J. Alles acquired 3,260 shares of Celgene stock in a transaction on Thursday, February 8th. The stock was bought at an average cost of $91.90 per share, for a total transaction of $299,594.00. Following the completion of the transaction, the insider now owns 178,904 shares of the company’s stock, valued at approximately $16,441,277.60. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.95% of the company’s stock.

A number of large investors have recently bought and sold shares of the business. BlackRock Inc. raised its position in Celgene by 5.7% during the second quarter. BlackRock Inc. now owns 56,725,342 shares of the biopharmaceutical company’s stock worth $7,366,919,000 after acquiring an additional 3,084,227 shares during the period. Vanguard Group Inc. raised its position in Celgene by 3.1% during the second quarter. Vanguard Group Inc. now owns 53,527,210 shares of the biopharmaceutical company’s stock worth $6,951,579,000 after acquiring an additional 1,610,056 shares during the period. Jennison Associates LLC raised its position in Celgene by 11.5% during the third quarter. Jennison Associates LLC now owns 14,962,407 shares of the biopharmaceutical company’s stock worth $2,181,818,000 after acquiring an additional 1,546,673 shares during the period. FMR LLC raised its position in Celgene by 5.9% during the second quarter. FMR LLC now owns 12,594,467 shares of the biopharmaceutical company’s stock worth $1,635,643,000 after acquiring an additional 697,250 shares during the period. Finally, Franklin Resources Inc. raised its position in Celgene by 3.3% during the second quarter. Franklin Resources Inc. now owns 11,080,093 shares of the biopharmaceutical company’s stock worth $1,439,025,000 after acquiring an additional 349,974 shares during the period. Institutional investors own 78.10% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece was published by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The correct version of this piece can be accessed at https://www.dailypolitical.com/2018/02/13/celgene-celg-upgraded-by-barclays-to-overweight.html.

Celgene Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

The Fly

Analyst Recommendations for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.